Clin2
NCT07035002Possibly a fitRecruiting

PD-1 knockout TILs for advanced colorectal cancer

Colorectal Cancer (CRC)Tumor Infiltrating LymphocytesPD-1

Part of Cancer, Digestive system clinical trials.

This trial tests a new therapy where immune cells (TILs) from your tumor are modified to fight cancer more effectively. It's for people with advanced colorectal cancer who can't get standard treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
29 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You must have advanced colorectal cancer that standard treatments can't help anymore.
  • You're willing to have surgery or a biopsy to get tumor tissue for making the treatment.
  • You are between 18 and 70 years old.
  • At least one tumor that can be measured by scans.
  • You're in fairly good physical condition (able to do daily activities).
  • Your organs (bone marrow, liver, kidneys) must be working well enough.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05087745Recruiting· Early Phase 1
TIL therapy for advanced solid tumors

This trial tests a treatment that uses your own immune cells, called TILs, to fight advanced solid tumors. The cells are taken from a biopsy of your tumor, multiplied in a lab, and then given back to you. It might help if you have tried other treatments without success, or if no standard treatment is available.

Hangzhou, Zhejiang
NCT05359393Not yet recruiting· Phase 2
Check whether anti-PD-1 plus other treatment helps rectal cancer

This Phase 2 trial studies a combination treatment that includes anti-PD-1 immunotherapy for rectal cancer that has spread to the liver or lungs but can still be surgically removed. It aims to improve outcomes compared with a standard approach by using immune therapy as part of treatment before/around surgery.

Shanghai, Shanghai Municipality
NCT06819280Recruiting
Immune cells for advanced colorectal cancer after first treatment

This trial tests whether your own immune cells, called tumor-infiltrating lymphocytes (TILs), can be grown in a lab and given back to you to fight advanced colorectal cancer. It is for people whose cancer has continued to grow after their first round of chemotherapy.

Shanghai, Shanghai Municipality
NCT06404281Recruiting· Phase 1
Modified immune cells for advanced solid tumors

This trial tests a new type of immune cell therapy (gamma-delta T cells that have been modified to target PD-1) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if these cells can help your immune system fight the cancer.

Changzhou
NCT06530303Recruiting· Phase 1/Phase 2
Personalized immune cell therapy for colorectal cancer

This trial tests a treatment made from your own immune cells (called TILs) that are taken from your tumor, grown in a lab, and given back to you along with immunotherapy. It is for people with advanced colon or rectum cancer who have run out of standard options.

Beijing, Beijing Municipality
NCT05451784Recruiting· Phase 1/Phase 2
PD-1 TIL therapy for advanced triple-negative breast cancer

This study tests an immune-cell treatment made from your tumor tissue. It aims to help people with advanced or metastatic triple-negative breast cancer by collecting PD-1–positive immune cells and giving them back after treatment.

Barcelona

Hear when a new Colorectal Cancer (CRC) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.